Skip to Content
Merck
  • Biosynthesis of the polyene macrolide antibiotic nystatin in Streptomyces noursei.

Biosynthesis of the polyene macrolide antibiotic nystatin in Streptomyces noursei.

Applied microbiology and biotechnology (2005-02-09)
Espen Fjaervik, Sergey B Zotchev
ABSTRACT

The polyene macrolide antibiotic nystatin, produced commercially by the bacterium Streptomyces noursei, is an important antifungal agent used in human therapy for treatment of certain types of mycoses. Early studies on nystatin biosynthesis in S. noursei provided important information regarding the precursors utilised in nystatin biosynthesis and factors affecting antibiotic yield. New insights into the enzymology of nystatin synthesis became available after the gene cluster governing nystatin biosynthesis in S. noursei was cloned and analysed. Six large polyketide synthase proteins were implicated in the formation of the nystatin macrolactone ring, while other enzymes, such as P450 monooxygenases and glycosyltransferase, were assumed responsible for ring "decoration". The latter data, supported by analysis of the polyene mixture synthesised by the nystatin producer, helped elucidate the complete nystatin biosynthetic pathway. This information has proved useful for engineered biosynthesis of novel nystatin analogues, suggesting a plausible route for the generation of potentially safer and more efficient antifungal drugs.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Nystatin Suspension, suspension, 10,000 unit/mL in DPBS, BioReagent, suitable for cell culture
Nystatin, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Nystatin, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Nystatin, ≥4,400 USP units/mg
USP
Nystatin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Nystatin, powder, γ-irradiated, BioXtra, suitable for cell culture